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ABSTRACT 
Conjugates of a dicarba analogue of octreotide, a potent somatostatin agonist whose receptors are 
overexpressed on tumor cells, with [PtCl2(dap)] (dap = 1-(carboxylic acid)-1,2-diaminoethane) (3), [(η
6
-
bip)Os(4-CO2-pico)Cl] (bip = biphenyl, pico = picolinate) (4), [(η
6
-p-cym)RuCl(dap)]
+
 (p-cym = p-
cymene) (5), and [(η
6
-p-cym)RuCl(imidazole-CO2H)(PPh3)]
+
 (6), were synthesized by using a solid-
phase approach. Conjugates 3-5 readily underwent hydrolysis and DNA binding whereas conjugate 6 
was inert to ligand substitution. NMR spectroscopy and molecular dynamics calculations showed that 
conjugate formation does not perturb the overall peptide structure. Only 6 exhibited antiproliferative 
activity in human tumor cells (IC50= 63 + 2 µM in MCF-7 cells and IC50= 26 + 3 µM in DU-145 cells) 
with an active participation of somatostatin receptors in cellular uptake. Similar cytotoxic activity was 
found in a normal cell line (IC50= 45 + 2.6 µM in CHO cells), which can be attributed to a similar level 
of expression of somatostatin subtype-2 receptor. These studies provide new insights into the effect of 
receptor-binding peptide conjugation on the activity of metal-based anticancer drugs, and demonstrate 
the potential of such hybrid compounds to target tumor cells specifically. 
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INTRODUCTION  
The overexpression of the receptors for many regulatory peptides in human tumor cells in comparison to 
their expression in normal cells, has prompted research on the use of such peptides in tumor targeting 
both for diagnostic and therapeutic purposes.
1,2,3
 From the therapeutical point of view, a promising 
approach for the treatment of cancer consists on the attachment of a cytotoxic drug to a peptide moiety 
with the aim of improving its activity and bioavailability. This targeted anticancer strategy will result in 
therapeutic agents with increased tumor selectivity and decreased toxicity in normal tissues.  
Among natural receptor-binding peptides, the neuroendocrine hormone somatostatin and its analogues 
have received much attention because of their high affinity against its five human receptors (sst1-
sst5).
1,3,4
 These receptors are overexpressed in various major tumor types, including lung, breast, 
prostate, adrenal and neuroendocrine tumors in comparison with normal tissues.
5
 The successful use of 
radiolabelled somatostatin for imaging and radionuclide therapy has prompted the development of new 
cyclic and acyclic analogues with better receptor affinity and higher stability under physiological 
conditions.
6
  
Octreotide,
7
 1 (Chart 1), a metabolically-stabilized cycloctapeptide analogue of somatostatin that 
includes D-amino acids to enhance resistance to enzymatic degradation and a cystine bridge to stabilize 
the pharmacophore β-turn, is particularly interesting because of its high affinity and selectivity for the 
receptor sst2,
6
 which is the receptor subtype most frequently found on tumor cells. This selectivity has 
allowed the development of derivatives such as [
111
In-DTPA]-octreotide and [
90
Y-DOTA-Tyr
3
]-
octreotide which are used in the clinics for molecular imaging and therapy of neuroendocrine tumors, 
respectively.
8
 Octreotide has also been conjugated to cytotoxic organic compounds such as doxorubicin, 
camptothecin and paclitaxel, with promising results in some cases because of the reduced toxicity and 
the increased selectivity of the conjugates compared with that of the free drug.
4,9
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Despite the successful history of cisplatin and its second-generation derivatives (carboplatin and 
oxaliplatin) in the treatment of some types of cancer,
10
 the severe toxic side-effects and the acquired or 
intrinsic resistance of certain tumors has focused research on other metal-based complexes in an effort to 
develop improved chemotherapeutic agents.
11,12
 Indeed, in addition to several platinum compounds, two 
ruthenium(III) coordination complexes, trans-[RuCl4(DMSO)(Im)]ImH (NAMI-A) and trans-
[RuCl4(Ind)2]IndH (NKP-1339) are currently on clinical trials.
13,14
  
In recent years, research on bioinorganic chemistry has also been focused on organometallic 
ruthenium(II) and osmium(II) arene complexes since these compounds have shown promising in vitro 
and in vivo anticancer activities, including cell lines that have become resistant to cisplatin.
15,16,17,18,19
 
Ruthenium and its heavier congener osmium offer several advantages in comparison with platinum 
compounds, including the ability to bind to a wide variety of types of ligands, the availability of 
additional coordination sites in octahedral complexes, the possibility of controlling the shape of the 
complex and the changes in the oxidation state. It is also particularly relevant that they have a capacity 
to undergo ligand exchange in a similar way than cisplatin, which makes them particularly attractive for 
developing new anticancer drugs. Unlike cisplatin which has two reactive Pt–Cl coordination bonds, 
some active organometallic piano-stool complexes have only one reactive site (Ru/Os–Cl). The aquation 
of the chlorido complexes, mostly suppressed in extracellular fluids (chloride concentration ∼100 mM), 
is triggered inside the cell nucleus by the low chloride concentration (4 mM), allowing the interaction of 
the active aqua species with biomolecules such as DNA.
20,21,22
  
Based on these precedents, a promising approach in the search of new metal-based anticancer drugs 
would consist of the conjugation of platinum and classical non-platinum metal complexes (e.g. 
ruthenium and osmium) to carrier molecules such as receptor-binding peptides. Indeed, given the 
overexpression of selective receptors for these peptides on the membrane of tumoral cells, it is expected 
that the peptide sequences will have a positive effect on the therapeutic properties of the metal-based 
drug (e.g. reduction of the toxic side-effects) since they will act as a “tumour-targeting devices”. With 
this idea in mind we have synthesized conjugates between a dichloridoplatinum(II) complex and 
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octreotide derivatives in which the disulfide bond had been replaced by CH2-CH2 or CH=CH linkages.
23
 
This chemical modification on the peptide does not substantially alter the binding affinity of the dicarba-
octreotide analogues for the sst2 receptor but increases the stability of the carrier biomolecule in the 
reductive cellular environment.
24
 In addition, we have recently described the synthesis and DNA 
ruthenation under visible light irradiation of a photoactivated ruthenium(II) arene complex conjugated to 
a dicarba analogue of octreotide.
25
 In recent years, several coordination or organometallic complexes 
have also been conjugated to carrier molecules such as receptor-binding peptides or known delivery 
peptides to improve both cellular uptake to cancer cells and cytotoxic activity of the metal-based 
drug.
26,27,28,29,30,31,32,33
 
Herein we report on the use of conjugates between octreotide and several metal complexes as new 
chemotherapeutic agents. In particular, the synthesis of hybrid compounds between the dicarba analogue 
of octreotide (2) and platinum(II), ruthenium(II) and osmium(II) metal complexes has been 
accomplished by efficient solid-phase procedures (compounds 3-6 in Chart 1). The influence of the 
attachment of the metal complex on the structure of octreotide has been studied by NMR spectroscopy 
and molecular dynamics, as well as the capacity of these conjugates to bind DNA. Finally, cellular 
uptake and cytotoxicity studies have been carried out in a normal cell line and two human tumoral cell 
lines. 
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Chart 1. Structure of the conjugates synthesized. Numbering of the amino acid residues follows that of 
native somatostatin. 
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EXPERIMENTAL PROCEDURES 
Materials and Methods. Unless otherwise stated, common chemicals and solvents (HPLC grade or 
reagent grade quality) were purchased from commercial sources and used without further purification. 
Peptide grade DMF was from Scharlau. Fmoc-protected amino acids, resins and coupling reagents for 
solid phase synthesis were obtained from Novabiochem, Bachem or Iris Biotech. Fmoc-Hag-OH was 
purchased from Bachem. Fmoc-L-threoninol p-carboxyacetal was synthesized following previously 
reported procedures.
34
 Solid-phase syntheses were performed manually in a polypropylene syringe fitted 
with a polyethylene disc. Second-generation Grubbs catalyst and Wilkinson’s catalyst were purchased 
from Aldrich. Milli-Q water was directly obtained from a Milli-Q system equipped with a 5000-Da 
ultrafiltration cartridge. Metal complexes (+)-[PtCl2(dap)] (7),
23
 (+)-[PtCl2(Etdap)] (15),
35
 [(η
6
-
bip)Os(4-CO2-pico)Cl] (8),
36
 [{(η
6
-p-cym)Ru(µ-Cl)Cl}2] (9), [(η
6
-p-cym)RuCl2(PPh3)] (10),
37
 and [(η
6
-
p-cym)RuCl(PPh3)2][PF6] (11)
38
 were synthesized and characterized as previously described. (L)-2,3-
Diaminopropionic acid methyl ester dihydrochloride
39
 and N
α
,N
β
-bis-(9-fluorenylmethyloxycarbonyl)-L-
2,3-diaminopropionic acid
40
 were synthesised as previously described. 5(6)-Carboxyfluorescein was 
purchased from Aldrich and octreotide acetate from Bachem. All the assayed compounds displayed a 
purity ≥95%, determined by HPLC analysis. 
The human breast cancer cell line MCF-7 and the human prostate carcinoma cell line DU-145 were 
obtained from the American Tissue Culture Collection (ATTC, Rockville, MD, USA). Chinese hamster 
ovary (CHO) cells were used as non-tumor cell line. The cells were maintained in Dulbecco’s modified 
eagle’s medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (GIBCO 
BRL, Grand Island, NY) at 37 ºC in a humidified atmosphere containing 5% CO2. The cells were 
passaged two times per week.  
NMR spectra were recorded at 25 ºC on Varian Gemini 300 MHz and Varian Mercury 400 MHz 
spectrometers using deuterated solvents. Tetramethylsilane (TMS) was used as an internal reference (δ 0 
ppm) for 
1
H spectra recorded in CDCl3 and the residual signal of the solvent (δ 77.16 ppm) for 
13
C 
Page 7 of 55
ACS Paragon Plus Environment
Bioconjugate Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 8
spectra. For CD3OD, acetone-d6, DMSO-d6 or D2O, the residual signal of the solvent was used as a 
reference. 
High resolution MALDI-TOF mass spectra were recorded on a 4800 Plus MALDI-TOF/TOF 
spectrometer (Applied Biosystems) in the positive-ion mode using 2,4-dihidroxybenzoic acid as a 
matrix. ESI mass spectra (ESI-MS) were recorded on a Micromass ZQ instrument with single 
quadrupole detector coupled to an HPLC. High resolution electrospray mass spectra (HR ESI MS) were 
obtained on an Agilent 1100 LC/MS-TOF instrument. 
Synthesis of metal-octreotide conjugates (3-6 and 12) and fluorescein-labelled peptides (13-14). 
Solid-phase peptide synthesis was performed on a Rink amide resin-p-MBHA (f = 0.34 mmol/g, 100-
200 mesh) using standard Fmoc/tBu chemistry with the following side-chain protecting groups: Boc (N
i
-
tert-butoxicarbonil, tryptophan and N
ε
-tert-butoxicarbonil, lysine), 
t
Bu (O-tert-butyl, threonine) and Trt 
(S-trityl, cysteine). The assembly of the dicarba analogue of octreotide was performed as previously 
described.
23,24
 Briefly, Fmoc-L-threoninol p-carboxyacetal (1.8 mol equiv) was first coupled using DIPC 
(1.8 mol equiv) and HOBt (1.8 mol equiv) in anhydrous DMF for 1 h. The following Fmoc-protected 
amino acids (2.4 mol equiv) were incorporated with HATU (2.3 mol equiv) and DIPEA (4.8 mol equiv) 
in anhydrous DMF for 1 h. Microwave-assisted ring closing methatesis using second generation Grubbs 
catalyst and hydrogenation reaction with Wilkinson’s catalyst were carried out as previously described.
23
 
Finally, 8-(9-fluorenylmethyloxycarbonyl-amino)-3,6-dioxaoctanoic acid (3 mol equiv) or γ-
aminoisobutyric acid (3 mol equiv) were coupled onto the cyclic dicarba analogue of octreotide 2 bound 
to resin with DIPC (3 mol equiv) and HOAt (3 mol equiv) in anhydrous DMF for 1 h. After removal of 
the Fmoc group (20% piperidine in DMF) from the Fmoc-protected linker-derivatized dicarba analogue 
of octreotide bound to resin, coupling or assembly of the metal complexes on the free N-terminal end 
was carried out as indicated for each metal. The reactor was protected from light by covering it with 
aluminium foil. 
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Side-chain deprotection and cleavage from the resin was performed simultaneously either with 
TFA/TIS/H2O 95:2.5:2.5 (peptides, fluorescein-labelled dicarba octreotide 13 and conjugate 4), 
TFA/phenol/H2O 95:2.5:2.5 (conjugates 3, 5, 6 and 12) or TFA/H2O/TIS/EDT 94:2.5:2.5:1 (fluorescein-
labelled octreotide 14) for 1 h at room temperature. Most of the TFA was removed by bubbling N2 into 
the solution, and the resulting residue was poured onto cold ether to precipitate the target compound. 
Analytical reversed-phase HPLC analyses were carried out on a GraceSmart RP C18 column (250x4 
mm, 5 µm, flow rate: 1 mL/min), using linear gradients of 0.045% TFA in H2O (solvent A) and 0.036% 
TFA in ACN (solvent B). In some cases, small-scale purification was carried out using the same 
column. Large-scale purification was carried out on a Jupiter Proteo semipreparative column (250 x 10 
mm, 10 µm, flow rate: 3-4 mL/min), using linear gradients of 0.1% TFA in H2O (solvent A) and 0.1% 
TFA in ACN (solvent B). After several runs, pure fractions were combined and lyophilized. 
-Platinum-octreotide conjugate 3: [PtCl2(dap)] (5 mol equiv) was coupled with DIPC (5 mol equiv) and 
NHS (10 mol equiv) in anhydrous DMF for 15 h at rt. Overall yield (synthesis + purification): 14%. 
Characterization: Rt= 14.2 min (analytical gradient: 20 to 60 % in 30 min); HR ESI MS, positive mode: 
m/z 1479.5574 (calcd mass for C60H88Cl2N13O14Pt [M+H]
+
: 1479.5598); HR MALDI-TOF MS, positive 
mode: m/z 1479.85 (calcd mass for C60H88Cl2N13O14Pt [M+H]
+
: 1479.5598), m/z 1501.87 (calcd mass 
for C60H87Cl2N13NaO14Pt [M+Na]
+
: 1501.5418). 
-Osmium-octreotide conjugate 4: [(η
6
-bip)Os(4-CO2-pico)Cl] (5 mol equiv) was coupled with DIPC (5 
mol equiv) and HOAt (5 mol equiv) in anhydrous DMF for 3 h at rt. Overall yield (synthesis + 
purification): 16%. Characterization: Rt= 20.2 min (analytical gradient: 20 to 60 % in 30 min); HR ESI 
MS, positive mode: m/z 1657.6621 (calcd mass for C76H94ClN12O16Os [M+H]
+
: 1657.6214); HR 
MALDI-TOF MS, positive mode: m/z 1679.60 (calcd mass for C76H92ClN12NaO16Os [M+Na]
+
: 
1679.6034). 
-Ruthenium(dap)-octreotide conjugate 5: N
α
,N
β
-bis-(9-fluorenylmethyloxycarbonyl)-L-2,3-
diaminopropionic acid (4 mol equiv) was coupled with HATU (3.9 mol equiv) in anhydrous DMF in the 
presence of DIPEA (8 mol equiv) for 1 h at rt. After removal of the Fmoc protecting groups, octreotide-
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bound resin was reacted with 9 (3 mol equiv) in the presence of LiCl (6.6 mol equiv) and NEt3 (7.2 mol 
equiv) in a DMF/EtOH 9:1 mixture at 100 ºC for 1 h under microwave irradiation (40 W). Overall yield 
(synthesis + purification): 10%. Characterization: Rt= 14.1 min (analytical gradient: 20 to 60 % in 30 
min); HR MALDI-TOF MS, positive mode: m/z 1448.40 (calcd mass for C70H100N13O14Ru [M-Cl-H]
+
: 
1448.6556).  
-Ruthenium-octreotide conjugate 6: 4-(1H-Imidazol-1-yl)benzoic acid (10 mol equiv) was first coupled 
with DIPC (10 mol equiv) and HOBt (10 mol equiv) in anhydrous DMF for 1 h at rt. Then, imidazole-
derivatized peptide-bound resin was reacted with 11 (3 mol equiv) in the presence of LiCl (3.3 mol 
equiv) and NEt3 (20 mol equiv) in a DMF/EtOH 9:1 mixture for 8 h at 50 ºC. Overall yield (synthesis + 
purification): 12%. Characterization: Rt= 14.6 min (analytical gradient: 30 to 100 % in 30 min); HR ESI 
MS, positive mode: m/z 1830.7240 (calcd mass for C95H116ClN13O14PRu [M]
+
: 1830.7234), m/z 
915.8672 (calcd mass for C70H102ClN13O14Ru [M+H]
2+
: 915.8656); HR MALDI-TOF MS, positive 
mode: m/z 1795.44 (calcd mass for C95H115N13O14PRu [M-Cl-H]
+
: 1794.7468). 
-Ruthenium-octreotide conjugate 12. Characterization: Rt= 17.7 min (analytical gradient: 30 to 100 % in 
30 min); HR ESI MS, positive mode: m/z 1768.6863 (calcd mass for C93H112ClN13O12PRu [M]
+
: 
1768.6867), m/z 884.8481 (calcd mass for C70H102ClN13O14Ru [M+H]
2+
: 884.8478). The MS data 
correspond to the dicarba analogue of octreotide with CH=CH linkage. 
-Fluorecein-labelled dicarba analogue of octreotide 13: Resin-bound linker-derivatized dicarba 
analogue of octreotide was allowed to react with 5(6)-carboxyfluorescein (5 mol equiv), DIPC (5 mol 
equiv) and HOAt (5 mol equiv) in anhydrous DMF for 16 h, protected from light. After filtration and 
washing, peptide-bound resin was treated with 20% piperidine/DMF (2 x 45 min). Overall yield 
(synthesis + purification): 40%. Characterization: Rt= 23.3 min (analytical gradient: 20 to 60 % in 30 
min); HR ESI MS, positive mode: m/z 1486.6572 (calcd mass for C78H92N11O19 [M+H]
+
: 1486.6571). 
-Fluorecein-labelled octreotide 14: Linear fluorescein-linker-derivatized octreotide was assembled on a 
Rink amide resin as described above with minor modifications: Fmoc-Hag-OH was replaced by Fmoc-
Cys(Trt)-OH and all Fmoc-protected amino acids, Fmoc-linker-OH and 5(6)-carboxyfluorescein (5 mol 
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equiv) were coupled with DIPC (5 mol equiv) and HOAt (5 mol equiv) in anhydrous DMF. After 
treatment with 20% piperidine/DMF (2 x 45 min) and acidic cleavage and deprotection, the linear 
peptide was dissolved (final concentration ca. 1 mM) in an aqueous ammonium hydrogencarbonate 
solution (5%, pH 7.7) and stirred at room temperature for 72 h (some drops of DMSO and MeOH were 
added after 24 h to improve solubility as well as to increase the oxidation rate). Overall yield (synthesis 
+ purification): 15%. Characterization: Rt= 23.5 min (analytical gradient: 20 to 60 % in 30 min); HR-
ESI MS, positive mode: m/z 1522.5673 (calcd mass for C76H88N11O19S2 [M+H]
+
: 1522.5699). 
Synthesis of metal complexes. -[(η6-p-cym)RuCl(dap)][PF6] (16). (L)-2,3-Diaminopropionic acid 
methyl ester dihydrochloride (0.068 g; 0.359 mmol) was reacted with complex 9 (0.1 g; 0.163 mmol) 
and NEt3 (513 µL; 1.63 mmol) in MeOH (15 mL). The mixture was stirred at room temperature for 3 h. 
The resulting solution was filtered and the volume of the filtrate reduced (to ca. 7 mL) in a rotary 
evaporator. Solid NH4PF6 (10 mol equiv) was added to the solution and stirred at room temperature for 
4 h. The resulting orange microcrystaline solid was filtered, washed with cold MeOH (10 mL) and dried 
in vacuo (68 mg, 40%). 
1
H NMR (400 MHz, DMSO-d6) δ (ppm): 1.22 (6H, d, J=6.8 Hz), 2.15 (3H, s), 
2.16-2.31 (2H, m); 2.7 (1H, sp, J=6.8 Hz), 3.02 (1H, br s); 5.04-5.14 (2H, br m), 5.32 (1H, d, J= 5.6 
Hz), 5.46 (1H, d, J= 6 Hz), 5.63 (1H, d, J= 6 Hz), 6.67 (1H, d, J= 5.6 Hz), 5.88-5.97 (2H, br m). 
13
C{
1
H} NMR (100 MHz, DMSO-d6) δ (ppm): 18.0, 22.5, 30.4, 58.9, 78.6, 79.4, 80.8, 81.2, 95.7, 101.6, 
176.8. HR ESI MS, positive mode: m/z 339.0650 (calcd mass for C13H21N2O2Ru [M-Cl-H]
+
: 339.0646). 
HR ESI MS, negative mode: m/z 373.0228 (calcd mass for C13H20ClN2O2Ru [M-2H]
-
: 373.0255). 
-[(η6-p-cym)RuCl2(Im-BzCOOMe)]. A suspension of 9 (200 mg, 0.33 mmol) in 10 mL of DCM was 
reacted with the methyl ester of the 4-(1H-Imidazol-1-yl)benzoic acid (1 mol equiv) and stirred at room 
temperature. Slowly the suspension dissolved and after 4 h diethyl ether was added with stirring to the 
resulting orange solution until it became turbid. The red microcrystalline product separated was isolated 
by filtration, washed several times with ether and dried under vacuo (165 mg, 50%). 
1
H NMR (400 
MHz, CDCl3) δ (ppm): 1.31 (6H, d, J=6.8 Hz), 2.24 (3H, s), 3.03 (1H, sp, J=6.8 Hz), 3.95 (3H, s), 5.32 
(2H. d, J=5.4 Hz), 5.51 (2H. d, J=5.4 Hz), 7.32 (1H, s), 7.43 (2H, d, J=8.4 Hz), 7.53 (1H, s), 8.14 (2H, 
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d, J=8.4 Hz), 8.38 (s, 1H). 
13
C{
1
H} NMR (100 MHz, CDCl3) δ (ppm): 20.1, 23.8, 32.2, 54.0, 83.0, 84.0, 
100.0, 104.4, 119.9, 122.4, 131.6, 133.1, 135.0, 139.9, 140.9, 167.2.  
-[(η6-p-cym)RuCl(Im-BzCOOMe)(PPh3)][PF6] (17). Complex [(η
6
-p-cym)RuCl2(Im-BzCOOMe)] (81 
mg, 0.16 mmol) was reacted with PPh3 (1 mol equiv) in methanol (5 mL) for 1 h under reflux. The 
resulting yellow solution was cooled to room temperature and ammonium hexafluorophosphate (1.1 mol 
equiv) dissolved methanol (1 mL) was added. A yellow crystalline solid was filtered off and washed 
several times with methanol and diethyl ether (106 mg, 90%). 
1
H NMR (400 MHz, acetone-d6) δ (ppm): 
1.19 (6H, dd, J=7.2 Hz), 1.83 (3H, s), 2.60 (1H, sp, J=7.2 Hz), 3.93 (3H, s), 5.36 (1H, dt, J= 6 Hz), 5.87 
(1H, d, J= 6 Hz), 6.07 (1H, d, J= 6 Hz), 6.20 (1H, d, J= 6 Hz), 7.44-7.54 (17H, m), 7.65 (2H, dt, J=10.4 
Hz), 8.15 (2H, d, J=8.8 Hz), 8.41 (1H, s). 
31
P{
1
H} NMR (acetone-d6) δ (ppm): 36.51 (s). 
13
C{
1
H} NMR 
(100 MHz, acetone-d6) δ (ppm): 19.1, 22.3, 24.2, 32.7, 53.9, 87.9, 90.2, 90.8, 95.7, 95.8, 105.0, 115.2, 
115.3, 121.8, 123.1, 130.2, 130.3, 132.0, 132.1, 132.5, 132.9, 132.8, 133.0, 136.1, 136.2, 141.1, 141.3, 
167.1. HR-ESI MS, positive mode: m/z 735.1488 (calcd mass for C39H39ClN2O2PRu [M]
+
: 735,1481), 
m/z 533.0729 (calcd mass for C28H29ClPRu [M-(Im-BzCOOMe)]
+
: 533,0739), m/z 497.0959 (calcd 
mass for C28H28PRu [M-(Im-BzCOOMe)-Cl-H]
+
: 497.0972). 
DNA binding studies. Complexation reactions were carried out in H2O (4 mM NaCl) at 37 ºC. The 
required volume of an aqueous solution of the corresponding metal-octreotide conjugate was mixed with 
the required volume of an aqueous solution of 
5´
dCATGGCT (1-2 mol equiv). Regarding conjugate 5, 
DNA binding studies were performed with the analogue with the CH=CH linkage isoster of octreotide 
(denoted as 5a). In all cases the solutions were 100 µM in the oligonucleotide. The evolution of the 
reactions was monitored by reversed-phase HPLC on Kromasil C18 columns (250 x 4.6 mm, 10 µm, 
flow rate: 1 mL/min), using linear gradients of aqueous triethylammonium acetate (0.05 M) (solvent A) 
and ACN (solvent B) or ACN/H2O 1:1 (solvent B’). Metal adducts were isolated after several HPLC 
runs by using analytical separation conditions. HR MALDI-TOF MS analysis was carried out in the 
negative mode using 2,4,6-trihidroxyacetophenone matrix with ammonium citrate as an additive. 
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Enzymatic digestions with 5’- and 3’-exonucleases (bovine spleen and snake venom phosphodiesterases, 
respectively) were performed as previously described.
41,42,43
 
Adduct 
5´
dCATGGCT-conjugate 3: Rt= 11.0 min (gradient: 15 to 50% B in 30 min); HR MALDI-TOF 
MS, negative mode: m/z 3501.0 (calcd mass for C128H171N38O55P6Pt [M-3H]
-
: 3500.95). MALDI-TOF 
MS after digestion with snake venom phosphodiesterase: m/z 2907.9 (-pCpT) (calcd mass for 
C109H146N33O42P4Pt [M-3H]
-
: 2907.89). MALDI-TOF MS after digestion with bovine spleen 
phosphodiesterase: m/z 2594.8 (-CpApTp) (calcd mass for C99H134N28O37P3Pt [M-3H]
-
: 2594.83), m/z 
2898.9 (-CpAp) (calcd mass for C109H147N30O44P4Pt [M-3H]
-
: 2898.88).  
Adduct 
5´
dCATGGCT-conjugate 4: Rt= 21.2 min (gradient: 5 to 90% B’ in 30 min); HR MALDI-TOF 
MS, negative mode: m/z 3715.8 (calcd mass for C144H178N37O57OsP6 [M-2H]
-
: 3715.02). MALDI-TOF 
MS after digestion with snake venom phosphodiesterase: m/z 2793.0 (-pGpCpT) (calcd mass for 
C115H141N27O38OsP3 [M-2H]
-
: 2792.88). MALDI-TOF MS after digestion with bovine spleen 
phosphodiesterase: m/z 2808.9 (-CpApTp) (calcd mass for C115H141N27O39OsP3 [M-2H]
-
: 2808.87), m/z 
3113.9 (-CpAp) (calcd mass for C125H154N29O46OsP4 [M-2H]
-
: 3112.92). 
Adduct 
5´
dCATGGCT-conjugate 5a: Rt= 20.5 min (gradient: 5 to 90% B’ in 30 min); HR MALDI-TOF 
MS, negative mode: m/z 3540.8 (calcd mass for C138H183N38O55P6Ru [M-3H]
-
: 3540.02). MALDI-TOF 
MS after digestion with snake venom phosphodiesterase: m/z 2617.6 (-pGpCpT) (calcd mass for 
C109H146N28O36P3Ru [M-3H]
-
: 2617.87). MALDI-TOF MS after digestion with bovine spleen 
phosphodiesterase: m/z 2633.7 (-CpApTp) (calcd mass for C109H146N28O37P3Ru [M-3H]
-
: 2633.87), m/z 
2937.7 (-CpAp) (calcd mass for C119H159N30O44P4Ru [M-3H]
-
: 2937.91). 
NMR spectroscopy. The samples of the conjugates were prepared by dissolving the appropriate amount 
of compound in 500 µL of H2O/DMSO-d6 8:2 to give 0.8 mM solutions. NMR spectra were acquired on 
Bruker Avance spectrometers operating at 600 or 800 MHz, and processed with Topspin software. 
NOESY experiments were acquired with mixing times of 150 and 300 ms, and TOCSY spectra were 
recorded with standard MLEV-17 spin-lock sequence, and 80-ms mixing time. Water suppression in 
H2O experiments was achieved by including a WATERGATE module in the pulse sequence prior to 
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acquisition. NMR experiments were carried out at temperatures ranging from 0 ºC to 25 ºC. The spectral 
analysis program Sparky
44
 was used for semiautomatic assignment of the NOESY cross-peaks and 
quantitative evaluation of the NOE intensities. Sequential assignment of the peptide moiety was carried 
out using standard 
1
H NMR techniques.  
Structural modeling. Molecular dynamics calculations were carried out with the program Sybyl X-1.3 
(Tripos Inc). Ten initial models for each conjugate were built from the dicarba analogue of octreotide 2 
coordinates.
24
 Metal complex coordinates were built from crystallographic structures of similar 
compounds.
36,45,
 Each of the initial structures was minimized and then submitted to 300 ps of molecular 
dynamics simulations. Explicit solvent and periodic boundary conditions were included in the 
calculations. The last 50 ps of each run was averaged and energy minimized. Backbone geometry of 
those peptide residues that do not exhibit significant chemical shift variations was loosely constrained 
by imposing dihedral angle restraints. Analysis of the representative structures was carried out with the 
programs Sybyl and MOLMOL.
46
 
Immunocytochemistry. MCF-7 cells were seeded on fibronectin-coated coverslips and allowed to 
attach overnight. Then, the cells were incubated at 37 ºC with medium containing 50 µM of 13 during 1, 
3 and 6 h, or with medium alone as control. After that, the cells were washed with cold PBS (Gibco 
BRL) and fixed with 4% paraformaldehyde in PBS for 15 min at 4 ºC. The cells nucleus were stained 
with 2 µg/mL Hoescht 33258 (excitation/emission: 352 nm/461 nm) during 15 min. After washing twice 
with cold PBS, the cells coverslips were mounted using a fluorescence mounting medium (Dako, 
Carpinteria, CA, USA) and examined using a Leica TCS-SP5 multiphoton and high-velocity spectral 
confocal microscope (Leica Microsystems, Nussloch, Germany). 
Internalization experiments with 13 and 14. The uptake efficiency of 13 and 14 by the cells was 
quantified by flow cytometry. The cells were seeded onto 12-well plates and allowed to attach for 24 h. 
Next, the cells were treated at 37 ºC with 50 µM of either 13 or 14 during 1, 3 and 6 h. After rinsing the 
cells three times with cold PBS, the cells were harvested by trypsinization and the fluorescence of the 
cells, corresponding to the uptake of the Fluorescein-modified peptides, was analysed using a 
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FACSCalibur (Becton Dickinson Immunocytometry Systems, San Jose, CA) equipped with the 
CellQuestTM software (Becton Dickinson). Fluorescence intensity was represented on a four orders of 
magnitude log scale (1–10.000). 10000 cells were analysed in each experiment. 
Cytotoxicity assays. The cytotoxicity of the conjugates and of the control complexes in MCF-7, DU-
145 and CHO cells was determined by the MTT assay. Aliquots of 4.000 DU-145 cells, 3.500 MCF-7 or 
2.000 CHO cells, were seeded onto flat-bottomed 96-well plates. 24 h later, the cells were treated for 72 
h with the compounds at concentrations ranging from 0 µM to 250 µM. After removal of the treatment, 
the cells were washed with PBS and incubated for 3 additional hours with 100 µL of fresh culture 
medium together with 10 µL of MTT (Sigma-Aldrich). The medium was discarded and DMSO (Sigma-
Aldrich) was added to each well to dissolve the purple formazan crystalls. Plates were agitated at room 
temperature for 10 minutes and the absorbance of each well was determined on a Multiscan Plate 
Reader (ELX800, Biotek, Winooski, USA) at a wavelength of 570 nm. Three replicates were used in 
each experiment. For each treatment, the cell viability was determined as a percentage of the control 
untreated cells, by dividing the mean absorbance of each treatment by the mean absorbance of the 
untreated cells. The concentration that reduces by 50% the cell viability (IC50) was established for each 
compound. 
Ruthenium accumulation in cancer cells. For ruthenium cellular uptake studies, 1.5 x 10
6 
MCF-7 cells 
were plated in 100 mm Petri dishes and allowed to attach for 48 h. Next, the plates were exposed to the 
ruthenium-octreotide conjugate 6 or to the unconjugated ruthenium complex 17 at a concentration 
corresponding to a fifth of their IC50 (12.5 µM and 0.66 µM, respectively). Additional plates were 
incubated with medium alone as negative control. After 24 h of incubation, the cells were rinsed three 
times with cold PBS and harvested by trypsinization. The number of cells in each sample was counted 
manually in a haemocytometer using the trypan blue dye exclusion test. Then the cells were centrifuged 
to obtain the whole cell pellet for ICP-MS analysis. All experiments were conducted in triplicate. 
ICP-MS analysis. The whole cell pellets were dissolved in 300 µL of concentrated 72 % v/v nitric acid, 
and the samples were then transferred into wheaton v-vials (Sigma-Aldrich) and heated in an oven at 
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373 K for 18 h. The vials were then allowed to cool, and each cellular sample solution was transferred 
into a volumetric tube and combined with washings with Milli-Q water (1.7 mL). Digested samples 
were diluted 10 times with Milli-Q to obtain a final HNO3 concentration of approximately 2.5% v/v. 
Ruthenium content was analyzed on an ICP-MS Perkin Elmer Elan 6000 series machine at the Centres 
Científics i Tecnològics of the Universitat de Barcelona. The solvent used for all ICP-MS experiments 
was Milli-Q water with 1% HNO3. The ruthenium standard (High-Purity Standards, 1000 µg/mL + 5 
µg/mL in 2% HCl) was diluted with Milli-Q water to 100 ppb. Ruthenium standards were freshly 
prepared in Milli-Q water with 1% HNO3 before each experiment. The concentrations used for the 
calibration curve were in all cases 0, 1, 2, 5 and 10 ppb. The isotope detected was 
101
Ru and readings 
were made in triplicate. Rhodium was added as an internal standard at a concentration of 10 ppb in all 
samples. 
SSTR2 expression analysis. SSTR2 expression on MCF-7, DU-145 and CHO cells surface was 
determined by double immunofluorescence. The cells were first fixed with PBS-1.5% formaldehyde and 
permeabilized with PBS-0.2%Tween 20 (Biorad). Then the cells were incubated with a monoclonal 
antibody against human sst2 receptor (R&D systems) during 30 min at 4 ºC. After rinsing the cells with 
PBS, the cells were incubated 30 min at 4 ºC in the presence of the Alexa-Fluor 488-conjugated goat 
anti-mouse IgG antibody (Invitrogen). Cells were washed again and the fluorescence was analyzed using 
a flow cytometer (FACSCalibur, Becton Dickinson Immunocytometry Systems, San Jose, CA) equipped 
with the CellQuestTM software (Becton Dickinson). The fluorescence intensity of the cells was 
represented on a four orders of magnitude log scale (1–10.000). 10000 cells were analysed in each 
experiment.  
Statistical analysis. The statistical analysis was performed with the SPSS statistical software for 
Windows (version 15.0; SPSS Inc., Chicago, IL, USA). Quantitative variables were expressed as mean 
and standard error (SE). The normality of the data was tested using the Kolmogorov-Smirnov test. The 
differences between data with normal distribution and homogeneous variances were analyzed using the 
parametric Student’s t test. A value of p<0.05 was considered significant. 
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RESULTS AND DISCUSSION 
Synthesis and characterization of conjugates between a dicarba analogue of octreotide and 
dichloridoplatinum(II) and osmium(II) complexes. In our previous work,
23
 cis-dichlorido-(1-
(carboxylic acid)-1,2-diaminoethane)platinum(II) complex, ([PtCl2(dap)]), was chosen as a cisplatin 
analogue since it can form the expected intrachain Pt-N7/5’G,N7/3’G chelates upon reaction with DNA. 
The attachment of the platinum complex to the γ-aminoisobutyryl-derivatized dicarba analogue of 
octreotide (2) was carried out on a solid-phase through the formation of an amide bond between its 
carboxylic function and the amine group of the spacer. Although the conjugate was able to bind to DNA 
in the same way as cisplatin, its low solubility in water precluded the evaluation of its biological 
activity. In order to improve the aqueous solubility for all the target conjugates, 3-6 (Chart 1), a 
polyethylenglycol spacer has been introduced between the peptide sequence and the metal complex. This 
spacer is expected to be sufficiently long to keep the metal complex away from the pharmacophore 
sequence.  
Following our previous results on the synthesis of platinum(II)-octreotide conjugates, a stepwise solid-
phase strategy has been used for the preparation of conjugates 3-6. This approach is particularly useful 
in this case since it allows the regioselective introduction of the metal complex at the N-terminal end of 
the cyclic peptide. Otherwise, in a solution-phase approach the ε-NH2 of the Lys residue would compete 
with the N-terminal amino group of octreotide. In order to increase the stability of the metal-octreotide 
conjugates, the CH2-CH2 linkage has been chosen as a disulfide isoster since this modification keeps a 
higher selectivity for sst2 somatostatin receptor than the CH=CH linkage.
24
 
First, the linear peptide was synthesized manually on a Rink amide resin-p-MBHA using standard 
Fmoc-tBu methodology (Scheme 1). All suitably-protected Fmoc-amino acids were incorporated with 
HATU in the presence of DIPEA in anhydrous DMF as a solvent. As previously described,
23,24
 Fmoc-
protected threoninol functionalized as the p-carboxybenzaldehyde acetal was first anchored to the solid 
support. In addition, the two cysteine amino acids in octreotide were replaced by allyl glycine residues to 
perform the cyclization reaction. Once the linear peptide precursor had been assembled, on-resin 
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microwave-assisted ring closing metathesis was carried out with second-generation Grubbs catalyst for 1 
h at 100 ºC. Then, hydrogenation of the double bond using Wilkinson’s catalyst afforded the protected 
cyclic saturated dicarba analogue of octreotide (2) bound to the resin. Finally, a Fmoc-protected 
polyethylenglycol linker, 8-(9-fluorenylmethyloxycarbonyl-amino)-3,6-dioxaoctanoic acid, was 
incorporated at the N-terminal end using HATU as a coupling reagent.  
 
Scheme 1. Schematic representation of the solid-phase approach used for the synthesis of conjugates 3 
and 4. 
The final step involved the removal of the Fmoc protecting group of the spacer (20% piperidine in 
DMF) and the incorporation of the required metal complex onto the free amino function of the linker. 
For the synthesis of conjugate 3, [PtCl2(dap)] (7) was coupled using DIPC and NHS in anhydrous DMF 
(15 h at rt, protected from light).
23
 Cleavage from the resin and removal of the protecting groups were 
carried out by treatment with a TFA/phenol/H2O cocktail (95:2.5:2.5) for 1 h at rt. Reversed-phase 
HPLC analysis of the crude revealed a main double peak. Both peaks were isolated by semipreparative 
HPLC and characterized by HR MALDI-TOF and ESI MS and NMR as the expected diastereomeric 
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dichloridoplatinum(II)-octreotide conjugates, 3. The generation of both isomers accounts from the use of 
a racemic platinum(II) complex.  
Our next objective was focused on the conjugation of an organometallic osmium(II) complex to the 
dicarba analogue of octreotide. Among osmium complexes with anticancer activity, [(η
6
-
bip)Os(pico)Cl] is particularly interesting since it exhibits promising activity in human ovarian cancer 
cells.
47,48
 For this reason, we choose an analogue bearing a carboxylic function on the picolinate ligand, 
[(η
6
-bip)Os(4-CO2-pico)Cl] (8), which would allow the attachment to octreotide. This complex has been 
very recently conjugated to polyarginines with different chain lengths using solid-phase procedures.
30
 
Hence, for the synthesis of conjugate 4, [(η
6
-bip)Os(4-CO2-pico)Cl] was coupled either with PyBOP or 
the more reactive HATU in the presence of DIPEA in anhydrous DMF (Scheme 1). After cleavage and 
deprotection with a TFA/TIS/H2O cocktail (95:2.5:2.5; 1 h at rt, protected from light), reversed-phase 
HPLC analysis revealed a main peak (30-40%) which was isolated and characterized by HR MS and 
NMR as the target conjugate 4. The conversion yield was substantially increased (90%) when coupling 
was performed with DIPC and HOAt in anhydrous DMF for 3 h. It is important to mention that during 
HPLC analysis of conjugate 4, a less retained peak was always observed, which was characterized by 
MS as the aqua conjugate (substitution of Cl by H2O). This result reveals fast hydrolysis kinetics for this 
osmium(II) complex in comparison with that of the platinum(II) complex (see below). 
Synthesis and characterization of conjugates between a dicarba analogue of octreotide and 
ruthenium(II) arene complexes. Ruthenium-octreotide conjugates, 5 and 6, were synthesized on a 
solid-phase following a different strategy than that used for platinum and osmium conjugates (Scheme 
2). Thus, instead of synthesizing the required ruthenium complexes bearing a carboxylic function, we 
decided to incorporate the appropriate ligand at the N-terminal end of the linker-derivatized peptide, 
which would allow the assembly of the organometallic ruthenium(II) complex around it. This approach 
avoids some of the difficulties found during the synthesis of carboxylic acid-containing ruthenium 
complexes and it could be applied to the parallel synthesis of libraries of ruthenium-peptide conjugates.  
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First, we focused on mononuclear ruthenium(II) arene complexes of the type [(η
6
-arene)RuCl(XY)]
+
, 
where XY is a N,N-chelating ligand such as ethylenediamine. These compounds show high 
cytotoxicities both in vitro and in vivo, with IC50 values comparable to carboplatin in human ovarian 
cancer cell lines (e.g. 9 µM for [(η
6
-p-cym)RuCl(en)][PF6]).
49
 In addition, they form monofunctional 
adducts at guanine nucleobases on DNA.  
Attachment of [(η
6
-p-cym)RuCl(en)] to octreotide was planned through the ethylenediamine ligand, as 
perfomed for the dichloridoplatinum(II) conjugate, which would lead to conjugate 5 (Chart 1). In order 
to incorporate 2,3-diaminopropionic acid into the N-terminal amino function of the linker-derivatized 
dicarba analogue of octreotide bound to the resin, the required N
α
,N
β
-bis-(9-
fluorenylmethyloxycarbonyl)-L-2,3-diaminopropionic acid was synthesized by reaction between L-2,3-
diaminopropionic acid hydrochloride and 9-fluorenylmethyloxycarbonyl chloride. This Fmoc-protected 
chelating ligand was coupled with HATU in DMF in the presence of DIPEA for 1 h at rt (Scheme 2). 
After removal of the Fmoc protecting groups, the binding of the ruthenium arene to the chelating ligand 
was studied by reaction with the ruthenium dimer [{(η
6
-p-cym)Ru(µ-Cl)Cl}2] (9). Optimized conditions 
required microwave irradiation at 100 ºC for 1 h and the use of a slight excess of 9 (3 mol equiv) in the 
presence of LiCl (6.6 mol equiv) and NEt3 (7.2 mol equiv) in a DCM/EtOH 9:1 mixture. The use of 
microwave irradiation in combination with this solvent was proven to be particularly important to 
achieve a good conversion yield. However, 30-40% conversion yields where obtained when DMF 
replaced DCM and no irradiation was used (15 h heating at 60 ºC). These results might be attributed to 
the instability of 9 at high temperatures during a prolonged time. Cleavage from the resin and 
deprotection was performed by treatment with a TFA/phenol/H2O cocktail (95:2.5:2.5) for 1 h at rt. 
Reversed-phase HPLC analysis of the crude revealed a main peak (65%) which was isolated by 
semipreparative HPLC and characterized by HR MALDI-TOF and ESI MS as the expected ruthenium-
octreotide conjugate, 5.  
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Scheme 2. Schematic representation of the solid-phase approach used for the synthesis of conjugates 5, 
6 and 12. 
Once we had synthesized conjugate 5, we explored the possibility of assembling mononuclear 
ruthenium(II) arene complexes through a single monodentate ligand incorporated in the peptide 
fragment instead of using chelating ligands. On basis to the excellent antitumor activities of some 
ruthenium(II) three-legged “piano stool” complexes containing planar N-heteroaromatic sigma-bonded 
ligands and phosphine ligands,
50
 with IC50 values lower than that of cisplatin, we focused on compounds 
of the type [(η
6
-p-cym)RuCl(Im-Ph)(PPh3)]
+
, where Im-Ph is 1-phenyl-imidazole. The conjugation of 
such triphenylphosphine-containing complexes to octreotide was planned through the phenyl ring linked 
to the imidazole ligand, which would allow the coordination of the ruthenium moiety. As in previous 
metal complexes, the hydrolysis of the Ru-Cl bond was expected to generate corresponding aqua species 
reactive towards DNA binding.  
First, 4-(1H-Imidazol-1-yl)benzoic acid was coupled onto two batches of linker-octreotide resin with 
DIPC and HOBt in anhydrous DMF for 1 h at rt, where linker refers to γ-aminoisobutyryl group or the 
polyethylenglycol spacer (Scheme 2). The assembly of the metal complex was first explored with the γ-
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Abu linker-containing batch by using two ruthenium compounds, [(η
6
-p-cym)RuCl2(PPh3)] (10) and 
[(η
6
-p-cym)RuCl(PPh3)2]
+
 (11), since we hypothesized that the imidazole ligand could replace the more 
labile chlorido ligands. 10 was easily synthesized by refluxing dimer 9 with triphenylphosphine (2.3 mol 
equiv) in hexane for 15 h, whereas complex 11 was obtained from 10 by reaction with a slight excess of 
triphenylphosphine (2 mol equiv) in methanol at 35 ºC for 2.5 h.
37,38
 
Reaction of the imidazole-derivatized peptide-bound resin with complex 10 (4 mol equiv) was 
performed in the presence of NEt3 (16 mol equiv) in a DMF/EtOH mixture (3:1) for 8 h at 55 ºC. After 
treatment of the resin with a TFA/phenol/H2O cocktail (95:2.5:2.5), the desired conjugate 12 was 
detected in the crude (18%) together with the imidazole-derivatized octreotide (20%), as inferred by 
HPLC and MS analysis (Figure 1A).  
B
0 30
min
D
0 30
min
C
0 30
min
A
0 30
min
612
12
Im- -Abu-Oct Im- -Abu-Oct
 
Figure 1. Reversed-phase HPLC traces of the reaction crudes for the synthesis of conjugate 12 by using 
complex 10 (A) or 11 (B) in the absence of LiCl or 11 in the presence of LiCl (C). Reaction crude for 
the synthesis of conjugate 6 when 11 was used in the presence of LiCl (D). 
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We next investigated the reaction of octreotide-bound resin with complex 11 under the same conditions. 
Unfortunately, reversed-HPLC analysis only revealed the presence of the imidazole-derivatized peptide, 
which indicates that imidazole was not able to substitute the chloride ligand in 11 (Figure 1B). This 
negative result might be attributed to the high steric hindrance around the metal because of the two 
bulky PPh3 ligands. However, to our surprise, when the reaction of 11 (4 mol equiv) with the peptide 
was repeated in the presence of LiCl (4.4 mol equiv) and NEt3 (16 mol equiv) in a DMF/EtOH 9:1 
mixture for 8 h at 55 ºC, HPLC analysis of the cleaved, deprotected crude (TFA/phenol/H2O 95:2.5:2.5, 
1 h rt) showed the presence of a main peak (57%) which was isolated and characterized by MS as 
conjugate 12 (Figure 1C). Hence, imidazole is able to replace one of the two PPh3 ligands in 11 instead 
of the Cl ligand, thereby allowing the conversion yield of conjugate 12 to be improved in comparison 
with that obtained when complex 10 is used. As shown in Figure 1D, the assembly of the ruthenium 
complex by using these optimized conditions was almost quantitative onto the imidazole-derivatized 
octreotide resin that contains the polyethylenglycol linker, which allowed the target conjugate 6 to 
obtain with high yield (Scheme 2). This compound was isolated by semipreparative HPLC and fully 
characterized by HR MS and NMR. 
In order to gain insight on the mechanism of this reaction, complex 11 was mixed with LiCl (1.4 mol 
equiv) and NEt3 (1.9 mol equiv) in anhydrous DMF and heated at 55 ºC. As shown in the 
31
P NMR 
spectra (Figure 2), the single chemical shift corresponding to the two PPh3 ligands in 11 (δ: 20.0 ppm) 
disappeared after 4 h. The two new signals (δ: 23.2 and -6.4 ppm) were assigned to the PPh3 ligand in 
complex 10 and to the released PPh3, respectively. These results demonstrate the in situ generation of 
complex 10 from 11 because of the presence of LiCl. This reaction might have future applications in the 
synthesis of new ruthenium complexes for catalysis or biomedical applications. 
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Figure 2. Schematic representation of the transformation of complex 11 to 10 (left) and 
31
P NMR 
spectra of 11 (A) and of the reaction crude after heating 11 in the presence of LiCl and NEt3 for 4 h at 55 
ºC (B). 
Activation of metal-octreotide conjugates by aqueous hydrolysis. In general, the cytotoxic activity of 
metal-based anticancer drugs is intimately related with the processes that mediate their activation in 
aqueous media; these processes are known to facilitate the interaction of the metal, its ligands or the 
complex or a fragment with the biological target (e.g. DNA, RNA or proteins). In addition, aqueous 
stability is another fundamental prerequisite since it might condition their success in clinical 
development. Cisplatin and its analogues can be considered prodrugs since their activation is produced 
through the dissociation of anionic ligands.
22,51
 The resulting positively charged aqua species coordinate 
strongly to nuclear DNA while neutral complexes do not, which demonstrates that in these family of 
compounds the metal plays a functional role.
22
 Organometallic complexes containing a labile group 
prone to substitution can also be activated inside the cells through hydrolysis. As previously stated, the 
activation of piano-stool organometallic ruthenium(II) complexes of the type [(η
6
-arene)RuCl(XY)]
+
, 
where XY is a neutral chelating ligand, proceeds through the release of chloride ligand. The resulting 
aqua species is responsible for ruthenation of DNA by generating monofunctional adducts on guanine 
nucleobases. In a similar manner to cisplatin and related platinum(II) compounds, the high extracellular 
chloride concentration (100 mM) in comparison with that present in the nucleus and cytoplasm (4 and 
22.7 mM, respectively),
52
 ensures that the intact drug reaches its biological target before activation takes 
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place. In addition, a close correlation between cancer cell cytotoxic activity and the capacity of some 
ruthenium(II) arene complexes to undergo hydrolysis of the Ru-halide bond has been established.
53
 
Osmium(II) arene complexes containing N,N-chelating ligands, such as ethylenediamine, experience 
much slower ligand exchange kinetics than ruthenium analogues.
54
 The higher acidity of the water 
molecule bound to the osmium at physiological pH makes these compounds exist largely in their less 
reactive hydroxido form. These problems have been solved by using picolinate as chelating ligand since 
it increases both the hydrolysis rate and the basicity of the water molecule in the aqua species (e.g. [(η
6
-
arene)Os(pico)Cl]) and, for instance, generates compounds with similar anticancer activity as 
ruthenium-arene analogues.
36,47
 
On the basis to these precedents, we wanted to assess whether hydrolysis of the M-Cl bond occurs when 
Pt, Ru and Os complexes are conjugated to octreotide. The stability of conjugates 3-6 (Chart 1) was 
investigated in aqueous solution at different chloride concentrations mimicking the typical of blood 
plasma, cell cytoplasm and cell nucleus (100, 22.7 and 4 mM, respectively). In all cases, metal-
octreotide conjugates (10 µM) were incubated at 37 ºC for 24 h. In general, HPLC analysis showed that 
the peak of the parent chloride compound (e.g. Rt = 20.3 min for conjugate 4) evolved into a new less 
retained peak (Rt =16.9 min), which was isolated and characterized by ESI MS as the aqua conjugate 
(substitution of Cl by H2O).  
As previously found in some osmium(II) complexes,
48
 the hydrolysis extent of conjugate 4 was highly 
dependent on the NaCl concentration. Almost 95% of the conjugate was hydrolysed in the 4 mM NaCl 
solution but the hydrolysis was substantially decreased in the more concentrated solutions of NaCl 
(Table 1). These results indicate that the covalent attachment of the peptide does not interfere with the 
hydrolysis properties of this osmium complex and,
48
 more importantly, that the aqua species is not 
deactivated by reaction with amino acids from the carrier peptide. Similar results were obtained for the 
ruthenium conjugate 5 at the 4 mM chloride concentration. However, the extent of hydrolysis of the Ru-
Cl bond was substantially decreased at the higher NaCl concentrations (Table 1).  
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Regarding conjugate 3, the hydrolysis of the Pt-Cl bond occurred to a lower extent than for conjugates 4 
and 5 (only 16% after 24 h in 4 mM NaCl solution), and it was almost abolished at higher chloride 
concentration.  
On basis to these results, it is expected that octreotide in conjugates 3 and 4 will have a positive effect 
on the delivery of the less reactive intact prodrug whilst outside the cell but, once in the cell cytoplasm 
and, particularly, in the cell nucleus, Pt and Os complexes will be selectively activated through 
hydrolysis to generate a species reactive towards DNA binding. However, hydrolysis of conjugate 5 in 
the blood plasma and in the cell cytoplasm might have important consequences for its biological activity 
since the metal complex could be deactivated by reaction with other potential ligands such as peptides or 
proteins. 
To our surprise, no hydrolysis occurred in the case of conjugate 6 upon incubation for 24 h at 37 ºC, as 
inferred by HPLC analysis together with MS (see below). 
 % aqua adduct % DNA adduct 
conjugate 4 mM NaCl 22.7 mM NaCl 100 mM NaCl 4 mM NaCl 
3 16 7 3 42 
4 95 35 12 49 
5a
a 97 83 74 37 
6 0 0 0 0 
Table 1. Percentage of aqua adduct formation in water at chloride levels typical of blood plasma (100 
mM), cell cytoplasm (22.7 mM) and cell nucleus (4 mM), and percentage of the conjugate-DNA adduct 
formation in aqueous 4 mM NaCl. 
a
See the experimental section. 
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DNA binding studies. In general, the chlorido species of Pt(II), Ru(II) and Os(II) complexes are 
relatively less reactive towards DNA nucleobases in comparison with the aqua adducts. The chloride 
concentration in the nucleus of cells (ca. 4 mM) is much less than that in the cytoplasm (ca. 22.7 mM) or 
outside cells (ca. 100 mM) which favors the formation of reactive aqua adducts in the vicinity of DNA. 
We incubated conjugates 3-6 in 4 mM NaCl at 37 ºC with the short DNA oligonucleotide, 
5’
dCATGGCT. This oligonucleotide contains the target GG sequence of the anticancer drug cisplatin 
and is known to give the expected platinum 1,2-intrastrand GG chelates upon reaction either with 
cisplatin, [Pt(en)Cl2] or a dichloridoplatinum(II) conjugate of a dicarba analogue of octreotide.
23,41
 
In the case of the platinum conjugate 3, HPLC analysis showed the formation of a new peak with higher 
retention time than the parent oligonucleotide (42% after 24 h; see Table 1), attributable to the 
hydrophobicity of the platinum-peptide fragment. This new product was isolated and characterized by 
HR MALDI-TOF MS as an adduct between 3 and 
5’
dCATGGCT in which both chloride ligands had 
been lost. As expected from previous results,
23
 MS analysis after enzymatic digestion with 5´- and 3´-
exonucleases (bovine spleen and snake venom phosphodiesterases, respectively)
42,43
 revealed the 
formation of a chelate between the platinum fragment of the conjugate and both guanines of the DNA 
chain (Scheme 3).  
G
G
H2
N
N
H2
Pt
O
5'dC A T G G C T
4 mM NaCl
H2O, 37ºC
5'
NH Octreotide
4 mM NaCl
H2O, 37ºC
Os
N
O
O
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O
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G
G
5'
Octreotide
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Scheme 3. Formation of adducts between conjugates 3-5 and the oligonucleotide. 
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When osmium- and ruthenium(dap)-octreotide conjugates were incubated with 
5’
dCATGGCT, a major 
monofunctional adduct was formed between the metal fragment of the conjugate and the DNA chain. In 
both cases, the high metalation yield (49% for 4 and 37% for 5) is in good agreement with the high 
degree of hydrolysis of the Os/Ru-Cl bonds. Enzymatic digestion in combination with MS revealed that 
in both cases metalation occurred at the guanine in the 5’ position (G4, see Scheme 3). This is a similar 
trend to that previously found with monofunctional platinum(II) complexes, such as {Pt(dien)}
2+
, since 
they react exclusively with the 5’G nucleobase in the 
5´
dCATGGCT sequence.
41
 The high affinity of 
similar ruthenium(II) arene complexes, such as [(η
6
-p-cym)RuCl(en)]
+ 
or [(η
6
-benzene)Ru(en)(OH2)]
2+
, 
for the N7 position of guanine over the other DNA nucleobases has been observed previously.
55,56,57
 
Regarding organometallic osmium(II) complexes with picolinate ligands, such as [(η
6
-
biphenyl)Os(picolinate)Cl]
+
, rapid binding to calf thymus DNA has also been found.
58
 
Finally, the reaction of the ruthenium-octreotide conjugate 6 with DNA was studied. In good agreement 
with the absence of hydrolysis of the Ru-Cl bond in this compound, ruthenation of 
5´
dCATGGCT was 
not observed even after 48 h. 
The overall results demonstrate that the activation of the M-Cl bond through hydrolysis in the Ru and Os 
conjugates seems to be very important for the binding to DNA, and that there is a strong preference for 
the guanine nucleobases, especially those located at the 5’ end in GG sequences. However, in the case of 
the Pt(dap)-octreotide conjugate, platination is observed despite the slow kinetics for the hydrolysis of 
the Pt-Cl bond in the low chloride medium as found in the nucleus. The high thermodynamic stability of 
the N7,N7-GG intrastrand adduct might account for this result.  
Efficiency of intracellular delivery of dicarba analogue of octreotide (2). Compared to octreotide 
(1), the binding affinity of the dicarba analogue of octreotide (2) (Chart 1) is slightly reduced for sst2, 
sst4 and sst5 receptors, although this reduction is smaller in the case of sst2 receptor (about 23-fold for 
sst2 vs 36 and 48-fold for sst4 and sst5, respectively).
6,24
 However, as previously stated, this high affinity 
toward sst2 receptor (44 nM) still makes 2 a suitable stabilized analogue of somatostatin to deliver 
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cytotoxic metal complexes into cancer cells. In order to check the capacity of internalization of analogue 
2 in our cell lines by confocal microscopy and flow cytometry, we labelled it with fluorescein. For the 
synthesis of the fluorescein-labelled dicarba analogue of octreotide (13), 5(6)-carboxyfluorescein was 
coupled on the linker derivatized peptide-bound resin by using DIPC and HOAt as coupling reagents. 
Washings with 20% piperidine/DMF before the final acidic treatment yielded a highly pure peptide.
59
 
As a control, fluorescein-labelled octreotide (14) was also synthesized using solid-phase procedures.  
 
Figure 3. Confocal microscopic imaging of the internalization of the fluorescein-labelled dicarba 
analogue of octreotide (13) in MCF-7 cells. Left: MCF-7 cells incubated with 50 µM of 13 for 1, 3 and 6 
h at 37 ºC or medium alone as a control (CTL). The cell nuclei were stained with Hoechst (blue). The 
localization of 13 is indicated by the green fluorescence. Right: Higher magnification image (1000 x) of 
a MCF-7 cell incubated with 50 µM of 13 for 3 h at 37 ºC. Arrows indicate the nuclear localization of 
13. 
Next, the internalization capacity of analogue 2 was determined by confocal microscopy, after the 
incubation of sstr2-expressing human breast cancer MCF-7 cells with 50  µM of the corresponding 
fluorescein-labelled peptide (13) for different times (1, 3 and 6 h). After 1 h of treatment, fluorescent 
vesicles, most likely endosomes, were visible in the cytoplasm of most of the examined cells, 
 
CTL 1
h
3
h
6
h
1h
3h 6h
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confirming the cellular uptake of the peptide (Figure 3). After 3 h and 6 h, the number and the 
fluorescence density of the vesicles markedly increased, revealing an intense internalization of 13 during 
this period of time. At these time points, the vesicles were mainly clustered at the periphery of the cell 
nucleus. Higher magnification (1000x) images from cells exposed to 13 for 3 h (Figure 3) revealed that 
although the fluorescence vesicles were located mainly in the cell cytoplasm, a small proportion of the 
fluorescence was localized within the cell nucleus. Some authors have reported that somatostatin ligands 
may accumulate in the cell nucleus,
60,61
 although the pathway for their nuclear localization remains to be 
elucidated.  
The qualitative observations in confocal microscopy studies were confirmed with quantitative data 
obtained by flow cytometry. As represented in Figure 4A, the mean intracellular fluorescence intensity, 
corresponding to the internalization of 13, increased over time. The intracellular fluorescence intensity 
increased from 78 + 16 at 1 h to 111 + 17 at 3 h and 182 + 39 at 6 h confirming an active cellular uptake 
of the peptide at these time points. In order to evaluate if 13 internalizes to a similar extent as native 
octreotide, MCF-7 cells were incubated in parallel with 14. As expected from the higher affinity of 
octreotide for the somatostatin receptors,
6,24
 the intracellular uptake of 14 was more elevated, by 40-
57%, compared with that obtained in cells incubated with 13. As shown in Figure 4B, the internalization 
kinetics was parallel for both peptides and it is also in good agreement with previous reports.
62,63
 
Despite the differences in the amount of internalized peptide, these results demonstrate that the dicarba 
analogue of octreotide (2) displays the internalization properties required to deliver the cytotoxic metal 
complexes into cancer cells. 
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Figure 4. Intracellular delivery efficiencies of fluorescein-labelled dicarba analogue of octreotide (13) 
and of fluorescein-labelled octreotide (14) in MCF-7 cells. MCF-7 cells were incubated with the 
peptides for 1 h, 3 h and 6 h at 37 ºC or medium alone (CTL). The fluorescence intensity of the cells, 
corresponding to the intracellular uptake of the peptides, was determined by flow cytometry. A: Flow 
cytometry histograms representing the fluorescence intensity of 10.000 cells on a four-decade log scale. 
Peptides 13 and 14 are depicted by solid and dashed lines, respectively. B: Kinetics of the cellular 
uptake of 13 and 14. Each point in the graphs represents the mean intracellular fluorescence intensity of 
three independent experiments + SE. 
Cancer Cell Cytotoxicity. To estimate the in vitro antitumor potential of the conjugates 3, 4, 5 and 6, 
their antiproliferative activity was determined in the MCF-7 cell line. The compounds were screened at a 
wide range of concentrations (from 0 to 250 µM) to determine the concentration that inhibits the cell 
growth by 50% (IC50). The conjugates that did not inhibit cell growth by more than 50% at 250 µM were 
considered to be inactive. As shown in Table 2, only conjugate 6 displayed a measureable 
antiproliferative activity, and even that was only moderate (IC50= 63.00 + 1.53). On basis to these 
results, we wondered whether the cytotoxic activity might be a consequence of the metal complex itself 
or of the conjugation to the peptide moiety. Hence, we tested the cytotoxicity of the parent metal 
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complex alone, including the ligand attached to the peptide. The following complexes were synthesized 
and used as controls (Chart 2): [PtCl2(Etdap)] (15), [(η
6
-p-cym)RuCl(dap)]
+
 (16) and [(η
6
-p-
cym)RuCl(Im-BzCOOMe)(PPh3)]
+
 (17). Although we planned to mask the carboxylic function in all the 
complexes as a methyl or ethyl ester to avoid a negative charge that might hinder cell uptake and lower 
their biological activity, the complex [(η
6
-p-cym)RuCl(Etdap)]
+
 spontaneously hydrolysed to 16 during 
the work up of the reaction. Regarding the osmium complex [(η
6
-bip)OsCl(4-CO2Et-pico)Cl)]
+
 (18), a 
moderate cytotoxic activity in the human ovarian A2780 and A2780cis cell lines (IC50= 44 and 61 µM, 
respectively) has been recently reported in comparison with that of [(η
6
-bip)OsCl(4-Me-pico)Cl)]
+
 
(IC50= 4.4 and 7.6 µM in the A2780 and A2780cis cell lines, respectively).
36
 Cytoxicity assays of the 
control complexes revealed that 17 was highly effective in MCF-7 cells, displaying an IC50 value (3.32 + 
0.54) comparable to that of cisplatin in this cell line (IC50= 3.04 + 0.25). In contrast, a moderate 
antiproliferative activity was obtained for complex 15 (IC50= 67.00 + 19.01) while complex 16 was non-
cytotoxic (Table 2).  
 IC50 (µM) 
Conjugates 3 4 5 6 
 > 250 > 250 > 250 63.00 + 1.53 
Complexes 15 - 16 17 
 67.00 + 19.01 - > 250 3.32 + 0.54 
Table 2. IC50 values of conjugates 3-6 and control complexes 15-17 in MCF-7 cells. IC50: Inhibitory 
concentration that reduce by 50% the cell viability. The cytotoxicity was determined by the MTT assay 
after 72 h of drug exposure. Data represents the mean + SE of at least three independent experiments.  
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Chart 2. Structure of the control metal complexes. 
Two important conclusions can be drawn from these results. First, a high cytotoxic activity of the metal 
complex itself seems to be crucial for the efficacy of the conjugates as antitumoral agents. Second, 
conjugation of the complexes to the peptide moiety diminishes their cytotoxic capacity. For example, the 
cytotoxic activity of the ruthenium(II) arene complex [(η
6
-p-cym)RuCl(Im-BzCOOMe)(PPh3)]
+
 (17) is 
reduced about 19-fold when conjugated to the octreotide analogue (6), whereas complexes with 
moderate activity such as [PtCl2(Etdap)] (15) or [(η
6
-bip)OsCl(4-CO2Et-pico)Cl)]
+
 (16),
36
 afford 
inactive peptide conjugates (3 and 4, respectively). On the other hand, the lack of activity for complex 
[(η
6
-p-cym)RuCl(dap)]
+
 (16) or its octreotide conjugate (5) might be attributable to the high hydrolysis 
rate of the Ru-Cl bond, which would cause deactivation of the activated species by reaction with other 
biomolecules before it reaches nuclear DNA. 
It is also interesting that the only conjugate that displays cytotoxic activity (6) does not interact with 
DNA, which can be attributed to the absence of hydrolysis of the Ru-Cl bond, even at a low chloride 
concentration (4 mM). This is also consistent with the fact that control complex 17 does not interact 
with double-stranded plasmid DNA after 48 h of incubation, as determined by electrophoretic mobility 
experiments (see Figure S-18 in the Supplementary Material). Similarly to conjugate 6, the aqua adduct 
of complex 17 was only formed after overnight incubation with a large excess of AgNO3, as inferred by 
1
H and 
31
P NMR (see the Supplementary Material). The overall results suggest that the cytotoxic activity 
of 6 and 17 might not be a consequence of their coordination to N-donor ligands from nucleic acids 
(DNA or RNA) or proteins. However, it cannot be rule out that their activation under physiological 
conditions occurs through coordination to sulfur-containing amino acids in peptides such as glutathione 
or in proteins.  
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In order to gain insight into the implication of somatostatin subtype 2 receptor on the cytotoxic activity 
of the ruthenium-octreotide conjugate 6, the cellular uptake of this compound was compared with that of 
the unconjugated ruthenium complex 17. Ruthenium accumulation (determined here as the net effect of 
influx and efflux of Ru) in the MCF-7 cancer cell line was determined by ICP-MS after a 24 h exposure 
to the compounds. Interestingly, the intracellular level of ruthenium after exposure to conjugate 6 
(143.14 + 16.6 pmol Ru/10
6
 cells) was higher than that of the parent complex 17 (68.01 + 2.2 pmol 
Ru/10
6
 cells). Such a significant difference between these compounds reveals that conjugation to the 
peptide moiety has a positive effect on the internalization of the ruthenium complex, thereby suggesting 
that the attachment of the metal complex to the peptide does not disturb its active conformation and 
hence its affinity toward somatostatin receptors is maintained (see below). Although the covalent 
attachment of a potential metal-based drug to a receptor-binding peptide such as octreotide is expected 
to increase the bioavailability, delivery and accumulation of the complex to cancer cells, it must also be 
borne in mind that the peptide moiety might also inhibit or weaken the interaction of the metal fragment 
with the final biological target (e.g., DNA, RNA, or proteins), which would compromise its cytotoxic 
activity.
25
 Release of the ruthenium fragment from the conjugate might be necessary to allow it to reach 
its target site. This might explain the apparently contradictory results from cytotoxicity and cellular 
uptake studies, since in this case the covalent attachment of the ruthenium complex to the dicarba 
analogue of octreotide 2 increases uptake and accumulation of the drug in the cancer cell whilst the 
cytotoxic activity of the final conjugate is reduced.  
Conformational analysis by NMR spectroscopy. It is well-known from NMR studies in water and in 
DMSO-d6 solution that octreotide (1) adopts a predominant type II’ β-turn conformation across residues 
Phe
7
-D-Trp
8
-Lys
9
-Thr
10
.
64,65
 The stability of this conformation together with the orientation of exocyclic 
residues (D-Phe
2
 and Thr-ol
15
) plays an important role in the binding of octreotide and its analogues to 
somatostatin receptors.
66,67
 Regarding the dicarba analogue of octreotide used in this work (2), 
D’Addona et al. have recently described that replacement of cystine by a CH2-CH2 linkage does not 
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substantially alter the secondary structure in the active region.
24 
These NMR studies also suggest that 
there exists a conformational equilibrium between the antiparallel β-sheet structural cluster and a second 
conformational ensemble involving folded structures for the C-terminal residues. This hypothesis is in 
good agreement with previously reported findings for 1 that indicate that C-terminal amino acids fold 
into a 310-helix-like array or in a similar helical ensemble.
66 
Furthermore, it is important to consider that 
the structure of 2 in the region of the N-terminal D-Phe
2
 and C-terminal Thr(ol)
15
 is significantly 
different from that previously reported for 1,
66
 which might explain the differences in affinity for 
somatostatin receptors.
24
 Given the implication of these amino acids both in the affinity and in the 
specificity for somatostatin receptors, we investigated whether the covalent attachment of metal 
complexes to the N-terminal end of 2 through a polyethylenglycol linker might alter the active 
conformation of the peptide and, in particular, the structure around D-Phe
2
 and Thr-ol
15
.  
In order to gain some insight into peptide conformation, conjugates 3, 4 and 6 were studied by 1D and 
2D 
1
H NMR spectroscopy. In all conjugates, significant line-broadening was observed at conjugate 
concentrations above 1 mM, suggesting that oligomerization takes place under these conditions. This 
effect is specially pronounced in the case of the osmium-octreotide conjugate (see the Supplementary 
Material). To avoid oligomerization, 2D NMR spectra were recorded at a peptide concentration of 0.8 
mM. Signals of the peptide were completely assigned using standard techniques (see Tables S1-3 in the 
Supplementary Material). Resonances of the linker and of ligands in the metal fragments were also 
indentified, although not all of them could be unambiguously assigned to specific protons.  
A comparison between the chemical shifts of the peptide fragment in the conjugates and the dicarba-
analogue of octreotide (2)
24
 indicates that residues D-Trp
8
-Lys
9
-Thr
10
-DsaC
14
-Thr(ol)
15
 have very 
similar chemical shifts, whereas significant differences are observed for protons of the amino acids D-
Phe
2
-DsaN
3
-Phe
7
 (Figure 5). This suggests that the peptide structure is only affected in the latter region. 
The chemical shift of Hα of D-Phe
2
 is notably shifted downfield. This shift is attributed to the covalent 
attachment of the linker to the α-amino group of this amino acid through an amide bond. Interestingly, 
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peaks for the NH protons of DsaN
3
 and Phe
7
 amino acids in all conjugates (and to a lesser extent for the 
Hβ signals) were shifted upfield.  
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Figure 5. Chemical shift differences for NH, Hα and Hβ protons between conjugates 3 (A), 4 (B) and 6 
(C) and the dicarba analogue of octreotide (2).
24  
 
Molecular dynamics calculations were carried out to gain further insight in the structural alterations 
induced in the peptide structure by the covalent attachment of the metal complex. The results are 
illustrated in Figure 6. The peptide backbone is not significantly altered with respect to the structure of 
the dicarba analogue of octreotide (2). In particular, the β-turn backbone geometry around residues D-
Trp
8
-Lys
9
-Thr
10
-DsaC
14
-Thr(ol)
15
 is totally preserved. The main changes occur in residues D-Phe
2
 and 
DsaN
3
. Side chain conformations are less defined than in 2. Linker and ligand fragments are mainly 
disordered. In some of the calculated conformers the ligand or the linker exhibit contacts with aromatic 
residues D-Phe
2
 and Phe
7
 as well as with DsaN
3
 (see Figure 6). These residues correspond to those that 
have changes in their 
1
H NMR chemical shifts with respect to the unmodified peptide. This is also in 
good agreement with the fact that some NOEs were observed between the linker and D-Phe
2
 (see Figure 
S-20 in the Supplementary Material).  
The NMR data and molecular dynamics calculations suggest that the covalent attachment of the metal 
complex does not substantially alter the global structure of the peptide. However, the aromatic ligands of 
the ruthenium and osmium complex in conjugates 4 and 6 as well as the linker appear to have a 
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tendency to interact with the aromatic residues located to their near side of the peptide sequence, which 
could be favoured by the high flexibility of the polyethyleneglycol linker. This is particularly important 
in the case of the Phe
7
 residue, since this amino acid is included in the so-called pharmacophore 
sequence of octreotide. These results support the hypothesis that the covalent attachment of both 
fragments might generate a significant population of peptide conformations with a decreased affinity for 
somatostatin receptors in comparison with that of the dicarba analogue of octreotide 2. However, the 
dicarba analogue of octreotide 2 still retains the ability to internalize metal complexes upon conjugation, 
as demonstrated cellular uptake experiments with 6 and 17.  
 
5
4
3
2
 
Figure 6. Model structures of the dicarba analogue of octreotide (2) and of conjugates 3, 4 and 6 (see 
Chart 1). Left: representative conformer. Right: ensemble with 10 conformers resulting from molecular 
dynamics calculations. Superposition was done by fitting the backbone peptide heavy atoms. 
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Selectivity of the ruthenium-octreotide conjugate (6). The main objective of a targeted strategy is the 
selective delivery of a cytotoxic drug to cancer cells in order to reduce toxicity to normal cells. 
Consequently, the reduction of the antiproliferative activity of a metal complex when conjugated with 
octreotide (Table 2) could be compensated by a selective and a more efficient delivery of the compound 
to the targeted cells. In order to corroborate this hypothesis, we determined whether the conjugation of 
the ruthenium(II) arene complex 17 to the octreotide analogue 2 (conjugate 6) is correlated with its 
vehiculization to tumour cells overexpressing sstr2, the most relevant receptor for octreotide 
internalization.
68
 To this end, we further analyzed the cytotoxic activity of conjugate 6 in human prostate 
tumour DU-145 cells as well as and in the Chinese hamster ovary (CHO) cell line, in order to assess the 
selectivity of the ruthenium-octreotide conjugate for cancer cells with respect to normal cells (Table 3). 
As shown in Fig. 7A, DU-145 cells were markedly more responsive to 6 than the MCF-7 and CHO 
cells, as the IC50 value (26.00 + 3.46) was 2.4-fold lower than in MCF-7 cells and about 1.7-fold lower 
than in CHO cells (IC50: 45.17 + 2.61) (Table 3). This difference in the cytotoxic activity of conjugate 6 
between the cell lines cannot be attributed to a different activity of the metal fragment in the different 
cells, as the control complex 17 cytotoxicity was higher in MCF-7 (IC50= 3.32 + 0.54) and more 
attenuated in DU-145 cells  (IC50=6.80 + 0.99) and CHO cells (5.8 + 0,01) (Figure 7B) (Table 3). 
                    Cell line, IC50 (µM) 
Compound MCF-7 DU-145 CHO 
6 63.00 + 1.53 26.00 + 2.00 45.17 + 2.61 
17 3.32 + 0.54 6.80 + 0.99 5.8 + 0.01 
Table 3. IC50 values of the ruthenium-octreotide conjugate 6 and control complex 17 in human cancer 
cell lines (MCF-7 and DU-145) and in normal cells (CHO). IC50: Inhibitory concentration that reduce by 
50% the cell viability. The cytotoxicity was determined by the MTT assay after 72 h of drug exposure. 
Data represents the mean + SE of at least three independent experiments. 
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Figure 7. Cytotoxic effect of conjugate 6 (A) and complex 17 (B) in the MCF-7, DU-145 and CHO cell 
lines. Cells were treated for 72 h with the indicated concentrations of each compound. The cell viability 
was determined using the MTT assay. Each point in the graphs represents the mean of three independent 
experiments + SE. 
In order to determine if the cytotoxic activity of 6 was related to the receptor expression on the cell 
surface, we next characterized the sstr2 levels by flow cytometry. As shown in Figure 8A, sstr2 
expression was detected on the three cell lines. Notably, sstr2 expression was significantly higher in the 
DU-145 and CHO cells than in MCF-7 cells (mean cell fluorescence intensity 347.5 + 54.6; 344.0 + 
50.56 and 206.7 + 14.27, respectively) (Figure 8B), which demonstrates that the cytotoxic activity of 6 is 
strongly correlated with sstr2 expression levels, specially in the DU-145 and MCF7 cells. However, 
although the CHO cells displayed similar sstr2 expression levels than DU-145, the toxicity of 6 was 
attenuated in these cells, suggesting some selective cytotoxic activity of the ruthenium-octreotide 
conjugate towards cancer cells with respect to normal cells.  
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Figure 8. Expression of the sst2 receptor on MCF-7, DU-145 and CHO cell lines. A: Representative 
flow cytometry histograms obtained after the indirect immunofluorescence staining of the cells. Solid 
lines represent the fluorescence intensity of the cells after the incubation with an antibody against sstr2 
together with a control secondary antibody. Dotted lines indicate the background staining with the 
secondary antibody alone. B: Each column in the graphs represents the mean fluorescence intensity of 
three independent experiments + SE in MCF-7, DU-145 and CHO cells *P<0.05 vs MCF-7 cells. 
 
As a very weak expression of sstr2 has been previously reported in CHO cells,
69
 the sstr2 expression in 
this cell line was additionally examined according to their mRNA expression levels. PCR analyses 
confirmed sstr2 gene expression in CHO cells, with similar mRNA levels than in MCF-7 cells (see the 
Supplementary Material). Our results are in keeping with different studies describing that somatostatin 
receptors can also be identified in a broad panel of normal tissues, as well as in the human immune 
system.
70
 As a consequence, new clinical applications for somatostatin analogues in several benign 
pathological diseases are emerging in addition to their role in malignant diseases.  
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All together, our results demonstrate a good correlation between the antitumour activity of the 
ruthenium-octreotide conjugate 6 and the expression of the sst2 receptor on the cell surface and reveal 
the potential of conjugation with receptor-binding peptides such as octreotide to deliver metal-based 
anticancer drugs specifically to cells overexpressing somatostatin subtype 2 receptor.  
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CONCLUSIONS 
In summary, in this work we have described a straightforward solid-phase methodology for the 
conjugation of a dichloridoplatinum(II) complex as well as three “piano-stool” organometallic 
ruthenium(II) and osmium(II) complexes to a dicarba analogue of octreotide, a potent somatostatin 
agonist whose receptors, particularly subtype 2, are overexpressed on the membrane of tumor cells. At 
nuclear Cl
-
 concentration (4 mM), platinum (3), osmium (4) and Ru(dap) (5) conjugates are activated 
through hydrolysis of the M-Cl, which correlates well with their DNA binding capacity, revealing in all 
cases a strong preference for guanine nucleobases. However, neither hydrolysis of the Ru-Cl nor 
interaction with DNA was observed in the case of the triphenylphosphine-containing ruthenium 
conjugate (6). Surprisingly, the latter conjugate displays antiproliferative activity but the rest of 
conjugates were non-cytotoxic. Additional cytotoxic experiments with control metal complexes and 
cellular uptake experiments by ICP-MS, as well as conformational analysis of metal-octreotide 
conjugates by 2D NMR spectroscopy and molecular dynamics calculations have allowed us to establish 
three general conclusions. First, a significant loss in the cytotoxic activity of the metal complex moiety 
always occurs when conjugated to the peptide sequence (e.g. IC50=3.32 + 0.54 in MCF-7 cells and 
IC50=6.80 + 0.99 in DU-145 cells for complex 17 vs IC50= 63.00 + 1.53 in MCF-7 cells and IC50= 26.00 
+ 2.00 in DU-145 cells for conjugate 6); hence, it seems to be important to use metal complexes with 
high cytotoxic activity in order to develop peptide-conjugates with active biological properties. Second, 
despite the presence of some altered amino acids in the pharmacophore sequence of octreotide, 
particularly at the N-terminal end of the peptide, the overall structure is essentially maintained in the 
conjugate, which suggests that the affinity for somatostatin receptors would not be compromised upon 
conjugation to a metal complex; this observation is in good agreement with the higher accumulation of 
ruthenium in cancer cells upon exposure to the ruthenium-octreotide conjugate 6 in comparison with 
that of the parent complex 17, which demonstrates that the peptide has a positive effect on the 
internalization of the ruthenium complex. The choice of the spacer is also important, not only to 
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improve aqueous solubility and to keep the metal complex away from the peptide, but also to reduce 
conformational freedom between both fragments in the conjugate. Third, the significantly higher 
expression of the sst2 receptor on DU-145 cells compared to MCF-7 cells is in good agreement with the 
intracellular uptake of the fluorescein-labelled dicarba analogue of octreotide (13), since it is markedly 
higher in the prostate tumour cells than in breast cancer cells. The fact that control complex 17 shows an 
attenuated cytotoxicity in DU-145 cells compared with MCF-7 cells suggests that the antitumoral 
activity of the ruthenium-octreotide conjugate 6 is correlated with the overexpression of the sst2 receptor 
on the cell surface. The cytotoxic activity of 6 in a non-tumour cell line (CHO) was similar to that found 
in cancer cells, a result which can be attributed to a similar level of expression of somatostatin subtype-2 
receptors. 
The overall results of this work demonstrate the potential of conjugation between metal-based anticancer 
drugs and receptor-binding peptides such as octreotide to target tumoral cells through binding to specific 
receptors, including somatostatin subtype 2 receptor, overexpressed in their membranes. In the near 
future, this receptor-targeted anticancer strategy is expected to generate new antitumor drugs with 
reduced side-effects and reduced toxicity in normal cells. The potential of this strategy will be increased 
by using novel approaches to circumvent some of the limitations found in this work, particularly new 
biological vectors in combination with photoactivated metal complexes
25
 or cleavable linkers
32
 in the 
biological media. Work is in progress in this direction to generate more specific metal-based anticancer 
drugs.  
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